bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prädiktive Regelung mit Timed-Elastic-Bands
Authors: Rösmann Christoph , Hoffmann Frank , Bertram Torsten 
Published: September 2014

Zusammenfassung
Der Beitrag beschreibt eine Erweiterung zur zeitoptimalen nichtlinearen modellprädiktiven Regelung. Die Trajektorie im
Zustandsraum und die Steuerfolge werden durch ein Timed-Elastic-Band (TEB) repräsentiert. Diese Beschreibung in Form eines TEBs
ermöglicht die Überführung der Regelungsaufgabe in ein nichtlineares, gewichtetes Ausgleichsproblem mit weichen
Nebenbedingungen, für welches effiziente numerische Optimierungsverfahren zur Verfügung stehen. In Analogie zu
modellprädiktiven Reglern wird die Planung der optimalen Trajektorie mit einer Zustandsrückführung im Regelkreis
integriert. Die vergleichende Analyse der durch den TEB-Ansatz optimierten Steuerfolge mit der analytischen, optimalen Lösung
belegt die Praxistauglichkeit der Methode.
The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review
Authors: Schuetz Philipp , Marlowe Robert J. , Mueller Beat 
Published: September 2014

AbstractPlasma proadrenomedullin (ProADM) is a blood biomarker that may aid in multidimensional risk assessment of patients with chronic obstructive pulmonary disease (COPD). Co-secreted 1:1 with adrenomedullin (ADM), ProADM is a less biologically active, more chemically stable surrogate for this pluripotent regulatory peptide, which due to biological and ex vivo physical characteristics is difficult to reliably directly quantify. Upregulated by hypoxia, inflammatory cytokines, bacterial products, and shear stress and expressed widely in pulmonary cells and ubiquitously throughout the body, ADM exerts or mediates vasodilatory, natriuretic, diuretic, antioxidative, anti-inflammatory, antimicrobial, and metabolic effects. Observational data from four separate studies totaling 1366 patients suggest that as a single factor, ProADM is a significant independent, and accurate, long-term all-cause mortality predictor in COPD. This body of work also suggests that combined with different groups of demographic/clinical variables, ProADM provides significant incremental long-term mortality prediction power relative to the groups of variables alone. Additionally, the literature contains indications that ProADM may be a global cardiopulmonary stress marker, potentially supplying prognostic information when cardiopulmonary exercise testing results such as 6-min walk distance are unavailable due to time or other resource constraints or to a patient’s advanced disease. Prospective, randomized, controlled interventional studies are needed to demonstrate whether ProADM use in risk-based guidance of site-of-care, monitoring, and treatment decisions improves clinical, quality-of-life, or pharmacoeconomic outcomes in patients with COPD.
Intertextuality in Chinese Courtroom Discourse
Authors: Shi Guang 
Published: September 2014

Abstract
Intertextuality, an important concept in semiotics, refers to the property texts have of being full of snatches of other texts. This paper analyzes specific and generic intertextuality of Chinese courtroom discourse. In the analysis of specific intertextuality, it is found that 1) “specific and exact news source” and “implicit news source” are indicated in the trials, while “seemingly real news source” is not found in the data; 2) “direct reporting”, “indirect reporting”, and “narrative report of speech act” are used in the trials, while “free indirect reporting” is not indicated. The analysis of generic intertextuality shows that courtroom discourse, especially the subgenre “evidence-producing”, is not only a mixture of different genres but also of different styles.
The Ethical Turn in Contemporary Western Semiotics
Authors: Guo Hong 
Published: September 2014

Abstract
The present paper is an abridged version of another paper of mine titled “The Ethical Turn of Contemporary Western Philosophy, Semiotics, and Linguistics” delivered at the 11th World Congress of Semiotics in response to related essays by Augusto Ponzio, Susan Petrilli, John Deely, and others. A review of contemporary Western philosophy reveals a confluence and integration of scientism and humanism, a linguistic turn, and a formation of postmodernism (poststructuralism), all of which marks an ethical turn (or focus) in contemporary Western philosophy. As semiotics is based on philosophy, and linguistics is a branch of semiotics, this ethical turn in philosophy concurrently occurs in contemporary Western semiotics and linguistics.
The Tartu Summer School in Semiotics 2013
Authors: Randviir Anti 
Published: September 2014

Abstract
This article provides an overview of the 8th Tartu Semiotics Summer School (in the series of summer schools established in 1964 by Juri Lotman). The event took place at Kääriku, Estonia, August 18-23, 2013, and was dedicated to the publication of the collective manifesto (titled Theses on the Semiotic Study of Cultures) that in 1973 established the field of the semiotics of culture. The scientific focus of the discussions and presentations concerned, from a semiotic point of view, the processes of autocommunication
The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality
Authors: Prüfer Nicole , Kleuser Burkhard , van der Giet Markus 
Published: September 2014

Abstract
The high-density lipoprotein (HDL) is one of the most important endogenous cardiovascular protective markers. HDL is an attractive target in the search for new pharmaceutical therapies and in the prevention of cardiovascular events. Some of HDL’s anti-atherogenic properties are related to the signaling molecule sphingosine-1-phosphate (S1P), which plays an important role in vascular homeostasis. However, for different patient populations it seems more complicated. Significant changes in HDL’s protective potency are reduced under pathologic conditions and HDL might even serve as a proatherogenic particle. Under uremic conditions especially there is a change in the compounds associated with HDL. S1P is reduced and acute phase proteins such as serum amyloid A (SAA) are found to be elevated in HDL. The conversion of HDL in inflammation changes the functional properties of HDL. High amounts of SAA are associated with the occurrence of cardiovascular diseases such as atherosclerosis. SAA has potent pro-atherogenic properties, which may have impact on HDL’s biological functions, including cholesterol efflux capacity, antioxidative and anti-inflammatory activities. This review focuses on two molecules that affect the functionality of HDL. The balance between functional and dysfunctional HDL is disturbed after the loss of the protective sphingolipid molecule S1P and the accumulation of the acute-phase protein SAA. This review also summarizes the biological activities of lipid-free and lipid-bound SAA and its impact on HDL function.
Utilization of a novel electrochemical 90Sr/90Y generator for the preparation of 90Y-labeled RGD peptide dimer in clinically relevant dose
Authors: Chakraborty Sudipta , Chakravarty Rubel , Sarma Haladhar Dev , Pillai Maroor Raghavan Ambikalmajan , Ashutosh Dash 
Published: September 2014

Abstract
The work reported in this paper provides a systematic study towards
the development of an optimized strategy for preparation of
a clinically relevant dose of 90Y-labeled dimeric RGD
peptide derivative, DOTA-E[c(RGDfK)]2 [DOTA-(RGD)2] for
in vivo targeted therapy utilizing 90Y obtained
from a novel electrochemical 90Sr/90Y
generator. The performance of the generator was evaluated to ensure
its suitability for providing 90Y in adequate quantity and
purity required for formulation of clinically relevant dose for
PRRT. 90Y-DOTA-(RGD)2 was synthesized in high yield
(86.2 ± 2.5%) and radiochemical purity
(98.4 ± 0.5%) using clinically relevant dose
(∼3.8 GBq) of 90Y. In vitro
stability studies revealed that the radiolabeled conjugate retained
its radiochemical purity in normal saline and human serum. Preliminary
biodistribution studies carried out in C57/BL6 mice bearing melanoma
tumors showed that the preparation exhibited significant tumor uptake
(5.30 ± 0.78% of injected activity at 30 min
post-injection) with good tumor to background ratio. The optimized
radiolabeling protocol seems to be an attractive strategy which is
largely viewed as a springboard to realize scope of developing
90Y labeled cyclic RGD peptides for targeted therapy of
tumors over-expressing integrin-α

v

β
3 receptors.
Crystal structure of sodium cadmium diaqua catena-[monoborodiphosphate]- hydrate, NaCd(H2O)2[BP2O8] · 0.8H2O
Authors: Ge M.-H. , Mi J.-X. , Huang Y.-X. , Zhao J.-T. , Kniep R. 
Published: September 2014

Abstract BCdH6NaO10.8P2, hexagonal, P6122 (No. 178), a = 9.713(1) Å, c = 16.136(3) Å, V = 1318.4 Å3, Z = 6, Rgt(F) = 0.047, wRref(F2) = 0.105, T = 273 K.
Crystal structure of caesium gallium(III) catena-[monohydrogenmonoborate- bis(monophosphate)], CsGa[BP2O8(OH)]
Authors: Mi J.-X. , Borrmann H. , Huang Y.-X. , Mao S.-Y. , Zhao J.-T. , Kniep R. 
Published: September 2014

Abstract BCsGaHO9P2, monoclinic, P121/c1 (No. 14), a = 9.259(1) Å, b = 8.6462(9) Å, c = 9.615(1) Å, = 103.059(6)0, V = 749.8 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) = 0.104, T = 295 K.
Crystal structure of Boc-L-Ile-ΔPhe-Ile-OCH3, C27H41N3O6 · H2O
Authors: Makker J. , Dey S. , Kumar P. , Singh T. P. 
Published: September 2014

Abstract C27H43N3O7, orthorhombic, P21212 (No. 18), a = 12.202(1) Å, b = 27.790(1) Å, c = 9.128(1) Å, V = 3095.2 Å3, Z = 4, Rgt(F) = 0.054, wRref(F2) = 0.180, T = 293 K.
Crystal structure of tetrakis(isopropylamino)silane, Si(NHC3H7)4
Authors: Engering J. , Nuss J. , Jansen M. 
Published: September 2014

Abstract C12H32N4Si, monoclinic, C121 (No. 5), a = 19.041(4) Å, b = 5.211(1) Å, c = 9.187(2) Å, β = 111.60(2)°, V = 847.6 Å3, Z = 2, Rgt(F) = 0.051, wRref(F2) = 0.061, T = 293 K.
Crystal structure of monoaqua(1,10-phenanthroline-N,N′)- succinatocobalt(II), Co(H2O)(C12H8N2)(C4H4O4)
Authors: Zheng Y.-Q. , Kong Z.-P. 
Published: September 2014

Abstract C16H14CoN2O5, triclinic, P1 (No. 2), a = 7.499(1) Å, b = 10.270(1) Å, c = 10.490(1) Å, α = 97.65(1)°, β = 106.80(1)°, γ = 100.57(1)°, V = 745.3 Å3, Z = 2, Rgt(F) = 0.058, wRref(F2) = 0.151, T = 293 K.
Crystal structure of diaqua-bis[N-(2-pyridyl)carbonylaniline]copper(II) dinitrate, Cu(C12H16N2O)2(H2O)2(NO3)2
Authors: Ramazani A. , Morsali A. 
Published: September 2014

Abstract C24H24CuN6O10, monoclinic, P121/c1 (No. 14), a = 7.441(2) Å, b = 11.458(2) Å, c = 14.850(3) Å, β = 95.941(5)°, V = 1259.4 Å3, Z = 2, Rgt(F) = 0.049, wRref(F2) = 0.126, T = 120 K.
Crystal structure of 2,2-dibenzyl-1,3-dimethyloxypropane, C19H24O2
Authors: Feng Y.-L. 
Published: September 2014

Abstract C19H24O2, monoclinic, P121/n1 (No. 14), a = 8.408(2) Å, b = 13.915(3) Å, c = 14.456(3) Å, β = 93.15(3)°, V = 1688.8 Å3, Z = 4, Rgt(F) = 0.042, wRref(F2) = 0.111, T = 293 K.
Crystal structure of ethylenediaminesilver(I) 4-nitrobenzoate hemi-hydrate, Ag(C2H8N2)(C7H4NO4) · 0.5H2O
Authors: Zhu H.-L. , Wang X.-J. , Sun X.-J. , Wang D.-Q. 
Published: September 2014

Abstract C9H13AgN3O4.50, monoclinic, C12/c1 (No. 15), a = 8.331(2) Å, b = 11.645(2) Å, c = 23.947(5) Å, β = 94.845(3)°, V = 2314.8 Å3, Z = 8, Rgt(F) = 0.030, wRref(F2) = 0.072, T = 298 K.
Crystal structure of ethylenediammonium di(4-chlor-benzoate), (C2H10N2)(C7H4O2Cl)2
Authors: Xia J. , Wang X.-J. , Sun X.-J. , Zhu H.-L. , Wang D.-Q. 
Published: September 2014

Abstract C16H18Cl2N2O4, monoclinic, C12/c1 (No. 15), a = 21.92(1) Å, b = 9.015(5) Å, c = 8.620(5) Å, β = 96.151(9)°, V = 1693.3 Å3, Z = 4, Rgt(F) = 0.064, wRref(F2) = 0.186, T = 298 K.
Crystal structure of bis[N-(2-aminopropyl)-salicylaldiminato)]cobalt(III) perchlorate, C20H26ClCoN4O6
Authors: Zhu H.-L. , Liu W.-.J. , Wang Y.-F. , Wang D.-Q. 
Published: September 2014

Abstract C20H26ClCoN4O6, monoclinic, P121/c1 (No. 14), a = 9.703(4) Å, b = 24.323(9) Å, c = 10.289(4) Å, β = 111.561(6)°, V = 2258.4 Å3, Z = 4, Rgt(F) = 0.049, wRref(F2) = 0.110, T = 298 K
Refinement of the crystal structure of silver(I) thiocyanate, AgSCN
Authors: Zhu H.-L. , Liu G.-F. , Meng F.-J 
Published: September 2014

Abstract AgCNS, monoclinic, C12/c1 (No. 15), a = 8.792(5) Å, b = 7.998(5) Å, c = 8.207(5) Å, β= 93.75(1)°, V = 575.9 Å3, Z = 8, Rgt(F) = 0.049, wRref(F2) = 0.086, T = 293 K.
Crystal structure of dilanthanum pentaiodide, La2I5
Authors: Mattausch Hj. , Oeckler O. , Simon A. 
Published: September 2014

AbstractI5La2, monoclinic, P121/m1(No. 11), a = 8.618(2)Å, b = 4.4038(9)Å, c = 14.580(3) Å, β = 90.20(3)°, V = 553.3 Å3, Z = 2, Rgt(F) = 0.026, wRref(F2) = 0.059, T = 293 K.
Crystal structure of tetraterbium hexabromide monosilicide, Tb4Br6Si
Authors: Mattausch Hj. , Oeckler O. , Simon A. 
Published: September 2014

Abstract Br6SiTb4, orthorhombic, Pbam (No. 55), a = 13.061(1) Å, b = 13.859(2) Å, c = 4.0407(4) Å, V = 731.4 Å3, Z = 2, Rgt(F) = 0.029, wRref(F2) = 0.071, T = 293 K.
Crystal structure of distrontium lithium magnesium trisilicide, Sr2(LixMg2-x)Si3 (x = 1)
Authors: Xie Q.-X. , Nesper R. 
Published: September 2014

Abstract LiMgSi3Sr2, orthorhombic, Cmcm (No. 63), a = 4.6179(5) Å, b = 19.488(2) Å, c = 7.1618(8) Å, V = 644.5 Å3, Z = 4, Rgt(F) = 0.029, wRref(F2) = 0.063, T = 293 K.
Refinement of the crystal structure of zirconium tritellurate(IV), ZrTe3O8
Authors: Noguera O. , Thomas P. , Masson O. , Champarnaud-Mesjard J.-C. 
Published: September 2014

Abstract O8Te3Zr, cubic, Ia3̅ (No. 206), a = 11.308(1) Å, V = 1446.0Å3, Z = 8, ρm= 5.50(3) g·cm-3, Rgt(F) = 0.024, wRref(F2) = 0.049, T = 293 K.
Crystal structure of tetraaquasamarium(III) tri(2-chlorofumarate) hexahydrate, Sm2(COOCHCClCOO)3(H2O)4 · 6H2O, with two-dimensional net structure
Authors: Zhao M.-G. , Shi J.-M. , Yu W.-T. 
Published: September 2014

AbstractC12H23Cl3O22Sm2, triclinic, P1 (No. 2), a = 8.877(3) Å, b = 9.413(3) Å, c = 9.554(3) Å, α = 103.778(5)°, β = 101.31 (5)°, ϒ = 93.954(5)°, V = 754.7 Å3, Z = 1, Rgt(F) = 0.056, wRref(F2) = 0.152, T = 293 K.
Crystal structure of ethylenediaminesilver(I) perchlorate, C2H8N2Ag(ClO4)
Authors: Zhu H.-L. , Zhang X.-M. , Yu Q. , Wang D.-Q. 
Published: September 2014

AbstractC2H8AgClN2O4, monoclinic, P121/n1 (No. 14), a = 8.676(3) Å, b = 9.869(3) Å, c = 8.822(3) Å, β = 111.240(4)°, V = 704.1 Å3, Z = 4, Rgt(F) = 0.032, wRref(F2) = 0.063, T = 293 K.
Crystal structure of bis(1-phenylimidazolium) tetrachlorocuprate(II), (C9H9N2)2(CuCl4)
Authors: Casellato U. , Ettorre R. , Graziani R. 
Published: September 2014

AbstractC18H18Cl4CuN4, monoclinic, C121 (No. 5), a = 14.109(3) Å, b = 10.263(2) Å, c = 15.290(3) Å, β = 102.61(3)°, V = 2160.6Å3, Z = 4, Rgt(F) = 0.040, wRall(F2) = 0.124, T = 293 K.
Crystal structure of [bis-tris(pyrazolyl)methanecopper(II)] [chlorobis( η2-benzoato)-η1-benzoato-manganate(II)] hydrate, Cu(C10H10N6)Mn(C7H5O2)3Cl · H2O
Authors: Moubaraki B. , Murray K. S. ,   Tiekink
Published: September 2014

AbstractC41H37ClCuMnN12O7, monoclinic, P121/n1 (No. 14), a = 15.946(3) Å, b = 13.26(2) Å, c = 20.766(5) Å, β = 106.49(2)°, V = 4209.3 Å3, Z = 4, Rgt(F) = 0.060, wRref(F2) = 0.155, T = 293 K.
Crystal structure of 3-(2,6-dichlorophenyl)-4,5-dihydro-7Hpyrano[ 4,3-d]isoxazol-7-one, C12H7Cl2NO3
Authors: Easton C. J. , Hughes C. M. M. , Tiekink E. R. T. 
Published: September 2014

AbstractC12H7Cl2NO3, monoclinic, P121/n1 (No. 14), a = 7.499(4) Å, b = 14.450(4) Å, c = 21.559(3) Å, β = 96.89(2)°, V = 2319.3Å3, Z = 8, Rgt(F) = 0.054, wRref(F2) = 0.134, T = 293 K.
Crystal structure of discandium tris-monohydrogenphosphate(III), Sc2(HPO3)3
Authors: Ewald B. , Prots Yu. , Kniep R. 
Published: September 2014

Abstract H3O9P3Sc2, hexagonal, P63/m (No. 176), a = 8.3055(7) Å, c = 7.697(1) Å, V = 459.8 Å3, Z = 2, Rgt(F) = 0.028, wRref(F2) = 0.061, T = 293 K.
Crystal structure of dirubidium dichromate(VI), Rb2Cr2O7, a fourth polymorph
Authors: Kolitsch U. 
Published: September 2014

Abstract Cr2O7Rb2, triclinic, P1̅ (No. 2), a = 7.433(1) Å, b = 7.571(2) Å, c = 7.832(2) Å, α = 109.44(3)°, β = 90.81(3)°, γ = 108.89(3)°, V = 389.6 Å3, Z = 2, Rgt(F) = 0.028, wRref(F2) = 0.076, T = 293 K.
Refinement of the crystal structure of Sb-I, at 2.22 GPa
Authors: Akselrud L. G. , Hanfland M. , Schwarz U. 
Published: September 2014

Abstract Sb, trigonal, R3̅m(No. 166), a = 4.2687(2) Å, c = 10.9244(6) Å, V = 172.4 Å3, Z = 6, R(P) = 0.066, R(I) = 0.059, T = 295 K, P = 2.22 GPa.
Refinement of the crystal structure of Bi-II, at 2.54 GPa
Authors: Akselrud L. G. , Hanfland M. , Schwarz U. 
Published: September 2014

Abstract Bi, monoclinic, C12/m1 (No. 12), a = 6.67256(1) Å, b = 6.1108(2) Å, c = 3.30013(9) Å, β = 110.412(2)°, V = 126.1 Å3, Z = 4, R(P) = 0.118, R(I) = 0.087, T = 295 K, P = 2.54 GPa.
Crystal structure of 4,4′-bipyridinum dibromide, (C10H10N2)Br2
Authors: Zhang B.-S. , Zheng Y.-Q. 
Published: September 2014

Abstract C10H10Br2N2, triclinic, P1̅(No. 2), a = 4.8975(6) Å, b = 7.654(1) Å, c = 7.9711(9) Å, α = 70.468(9)°, β = 87.029(9)°, γ = 77.15(1)°, V = 274.5 Å3, Z = 1, Rgt(F) = 0.034, wRref(F2) = 0.091, T = 293 K.
Refinement of the crystal structure of the δ-modification of tris(8-hydroxyquinoline) aluminum(III), δ-Al(C9H6NO)3, the blue luminescent Alq3
Authors: Rajeswaran M. , Blanton T. N. , Klubek K. P. 
Published: September 2014

Abstract C27H18AlN3O3, triclinic, P1̅̅̅̅̅ (No. 2), a = 6.181(1) Å, b = 13.268(3) Å, c = 14.430(3) Å, α = 66.06(3)°, β = 88.56(3)°, γ = 84.03(3)°, V = 1075.5 Å3, Z = 2, Rgt(F) = 0.108, wRref(F2) = 0.437, T = 293 K.
Crystal structure of di[potassium(diaza-18-crown-6)]dicaesium nonastannide( 4–) diethylenediamine, [K(C12H26N2O4)]2Cs2[Sn9] · 2C2N2H8, a polyanion 2∞[KCs2Sn9]– with low-dimensional arrangement of [Sn9] clusters
Authors: Hauptmann R. , Fässler T. F. 
Published: September 2014

Abstract C28H68Cs2K2N8O8Sn9, monoclinic, P121/c1 (No. 14), a = 13.897(3) Å, b = 16.091(3) Å, c = 26.432(5) Å, β = 91.03(3)°, V = 5909.7 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) = 0.127, T = 153 K.
Crystal structure of di[potassium(18-crown-6)]dipotassium nonastannide(4–)—diethylenediamine solvate (1:1.5), [K(C12H24O6)]2K2[Sn9] · 1.5C2N2H8
Authors: Hauptmann R. , Fässler T. F. 
Published: September 2014

Abstract C27H60K4N3O12Sn9, monoclinic, P121/n1(No. 14), a = 10.410(2) Å, b = 25.659(5) Å, c = 20.636(4) Å, β = 102.56(3)°, V = 5380.2 Å3, Z = 4, Rgt(F) = 0.030, wRref(F2) = 0.072, T = 150 K.
Crystal structure of di[potassium([2.2.2]crypt)]tetrapotassium octadecagermanide(6–)—ethylenediamine solvate (1:6), [K(C18H36N2O6)]2K4(Ge9)2 · 6C2N2H8
Authors: Hauptmann R. , Fässler T. F. 
Published: September 2014

Abstract C24H60Ge9K3N8O6, triclinic, P1̅ (No. 2), a = 9.408(2) Å, b = 13.606(3) Å, c = 19.507(4) Å, α = 84.74(3)°, β = 81.35(3)°, γ = 80.18(3)°, V = 2426.8 Å3, Z = 2, Rgt(F) = 0.064, wRref(F2) = 0.192, T = 150 K.
Crystal structure of dimethylamido-hexahydro-2-azepinato-bis[2-(trimethylsilylamino)-4-methylpyridinato]-titanium(IV), C26H46N6OSi2Ti
Authors: Kempe R. , Hillebrand G. 
Published: September 2014

Abstract C26H46N6OSi2Ti, triclinic, P1̅ (No. 2), a = 10.178(2) Å, b = 10.906(2) Å, c = 16.254(3) Å, α = 91.82(1)°, β = 102.60(2)°, γ = 112.81(2)°, V = 1609.5 Å3, Z = 2, Rgt(F) = 0.046, wRobs(F2) = 0.116, T = 293 K.
Crystal structure of ammonium oxo(peroxo)(pyridine-2,6-dicarboxylato- N,O,O′)aquavanadate(V), (NH4)[VO(O2)(H2O)(C7H3NO4)]
Authors: Tinant B. , Bayot D. , Devillers M. 
Published: September 2014

Abstract C7H9N2O8V, orthorhombic, Pcca (No. 54), a = 13.575(4) Å, b = 20.603(6) Å, c = 8.026(3) Å, V = 2244.8 Å3, Z = 8, Rgt(F) = 0.046, wRref(F2) = 0.155, T = 293 K.
Crystal structure of tris(N-(n-butyl)-4-methoxy-2-hydroxybenzaldimine)-tris(nitrato)lanthanum(III), La(C12H17NO2)3(NO3)3
Authors: Van Meervelt L. , Uytterhoeven K. , Van Deun R. , Binnemans K. 
Published: September 2014

Abstract C36H51LaN6O15, triclinic, P1̅̅ (No. 2), a = 11.455(2) Å, b = 13.859(3) Å, c = 14.101(4) Å, α = 98.50(2)°, β = 98.87(1)°, γ = 92.52(2)°, V = 2182.4 Å3, Z = 2, Rgt(F) = 0.035, wRref(F2) = 0.082, T = 289 K.
Crystal structure of di(μ-3,5-dinitrobenzoato-O,O′)di(μ-3,5-dinitrobenzoato-O,O:O′)di(3,5-dinitrobenzoato-O,O′)di(1,10-phenanthroline- N,N′)-diterbium(III), Tb2(C12H8N2)2(C7H3N2O6)6
Authors: Hu M.-L. , Xiao H.-P. , Wang S. , Li X.-H. 
Published: September 2014

Abstract C66H34N16O36Tb2, triclinic, P1̅̅ (No. 2), a = 12.027(7) Å, b = 12.908(7) Å, c = 13.210(7) Å, α = 104.086(7)°, β = 113.774(7)°, γ = 100.425(7)°, V = 1728.1 Å3, Z = 1, Rgt(F) = 0.025, wRref(F2) = 0.042, T = 298 K.
Crystal structure of diethylenetriaminesilver(I) perchlorate, Ag(C4H13N3)(ClO4)
Authors: Zhu H.-L. , Shao S.-C. , Ma J.-L. , Qiu X.-Y. , Yang S. , Sun L. 
Published: September 2014

Abstract C4H13AgClN3O4, orthorhombic, Pccn (No. 56), a = 17.730(7) Å, b = 7.162(3) Å, c = 15.891(7) Å, V = 2017.9 Å3, Z = 8, Rgt(F) = 0.047, wRref(F2) = 0.152, T = 298 K.
Crystal structure of bis[dinitrato-2,5,8-triaza-1,9-di(2-fluorobenzylnonanecopper( II)] monohydrate, Cu(C18H22F2N5O6)2 · H2O
Authors: Zhu H.-L. , Shao S.-C. , Ma J.-L. , Qiu X.-Y. , Yang S. , Sun L. 
Published: September 2014

Abstract C36H48Cu2F4N10O13, monoclinic, C1c1 (No. 9), a = 14.870(8) Å, b = 20.78(1) Å, c = 14.660(7) Å, β = 101.308(9)°, V = 4441.6 Å3, Z = 4, Rgt(F) = 0.053, wRref(F2) = 0.147, T = 298 K.
Crystal structure of di(2-aminopyridine)-tetrakis[N-(2-aminopropyl)-salicylaldiminato)]tricobalt(III) diperchlorate, Co3(C58H48N12O4)(ClO4)2
Authors: Zhu H.-L. , Yang S. , Shao S.-C. , Ma J.-L. , Qiu X.-Y. , Sun L. 
Published: September 2014

Abstract C58H48Cl2Co3N12O12, triclinic, P1̅̅̅̅ (No. 2), a = 11.640(3) Å, b = 11.693(3) Å, c = 12.218(3) Å, α = 78.968(5)°, β = 89.827(5)°, γ = 60.605(4)°, V = 1414.0 Å3, Z = 1, Rgt(F) = 0.062, wRref(F2) = 0.136, T = 293 K.
Crystal structure of bis(3,3′-diethyl-4-maleimidophenyl)methane, C25H22N2O4
Authors: Zhu H.-L. , Zhang H. , Ma J.-L. , Qiu X.-Y. , Yang S. , Sun L. 
Published: September 2014

Abstract C25H22N2O4, orthorhombic, Pccn (No. 56), a = 12.745(2) Å, b = 16.974(2) Å, c = 10.218(1) Å, V = 2210.4 Å3, Z = 4, Rgt(F) = 0.114, wRref(F2) = 0.300, T = 293 K.
Crystal structure of dimethylglyoxime 2-picoloylhydrazone, C10H12N4O2
Authors: Lin H. , Wu W.-S. 
Published: September 2014

Abstract C10H12N4O2, monoclinic, P121/c1 (No. 14), a = 5.7138(3) Å, b = 25.771(1) Å, c = 7.3379(4) Å, β = 100.385(2)°, V = 1062.8 Å3, Z = 4, Rgt(F) = 0.051, wRref(F2) = 0.170, T = 293 K.
Crystal structure of [bis(2-hydroxybenzylidenethiosemicarbazone)-iron(II)] hydrate, Fe(C16H16N6O2S2) · H2O
Authors: Wu W.-S. , Feng Y.-L. 
Published: September 2014

Abstract C16H18FeN6O3S2, monoclinic, P121/n1 (No. 14), a = 8.9754(5) Å, b = 18.229(1) Å, c = 11.5546(7) Å, β = 93.006(2)°, V = 1887.9 Å3, Z = 4, Rgt(F) = 0.039, wRref(F2) = 0.080, T = 293 K.
Crystal structure of diaqua-bis(pyridine)-μ2-squarato(1,3)-nickel(II), Ni(C4O4)(C5H5N)2(H2O)2
Authors: Kirchmaier R. , Altin E. , Lentz A. 
Published: September 2014

Abstract C14H14N2NiO6, orthorhombic, Pbca (No. 61), a = 7.914(1) Å, b = 12.020(2) Å, c = 15.718(3) Å, V = 1495.3 Å3, Z = 4, Rgt(F) = 0.026, wRref(F2) = 0.062, T = 293 K.
Crystal structure of nonafluoro-{N-[(E)-2-(4-hydroxyphenyl)diazenyl]-phenyl}-1-butanesulfonamide, C16H10F9N3O3S
Authors: Àlvarez Micó X. , Richter M. , Schwarz S. , Strähle J. , Ziegler T. , Subramanian L. R. 
Published: September 2014

Abstract C16H10F9N3O3S, triclinic, P1̅ (No. 2), a = 5.4635(2) Å, b = 10.266(1) Å, c = 17.645(2) Å, α = 105.731(6)°, β = 93.187(5)°, γ = 97.036(7)°, V = 941.3 Å3, Z = 2, Rgt(F) = 0.048, wRref(F2) = 0.134, T = 213 K.
Crystal structure of (±)-[(2R,3S)-3-(hydroxymethyl)oxiran-2-yl](phenyl)- methanone, C10H10O3
Authors: Greatrex B. W. , Taylor D. K. , Tiekink E. R. T. 
Published: September 2014

Abstract C10H10O3, orthorhombic, Pca21 (No. 29), a = 20.165(4) Å, b = 5.667(1) Å, c = 7.583(2) Å, V = 866.6 Å3, Z = 4, Rgt(F) = 0.072, wRref(F2) = 0.177, T = 223 K.